Joanne Louise Mitchell

Joanne Louise Mitchell

Auto-generated profile, based on publicly available information

Joanne Louise Mitchell

Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
CWClaire Whyte
Claire Whyte
GMGael B. Morrow
Gael B. Morrow
JMJoanne L. Mitchell
Joanne L. Mitchell
PCPratima Chowdary
Pratima Chowdary
NMNicola J Mutch
Nicola J Mutch
The global pandemic of coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D-dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients.

18 December 2014 in Blood
Verified
Journal Article
Open access
PDF file
JMJoanne L. Mitchell
Joanne L. Mitchell
ALAusra S. Lionikiene
Ausra S. Lionikiene
SFSteven R. Fraser
Steven R. Fraser
CWClaire Whyte
Claire Whyte
NBNuala A. Booth
Nuala A. Booth
NMNicola J Mutch
Nicola J Mutch
Key Points: Factor XIII-A is exposed in protruding caps on the activated platelet surface. Platelet FXIII-A exerts antifibrinolytic function by cross-linking α2AP to fibrin.

15 December 2016 in Blood
Verified
Journal Article
Open access
PDF file
JMJoanne L. Mitchell
Joanne L. Mitchell
ALAusra S. Lionikiene
Ausra S. Lionikiene
GGGeorgi Georgiev
Georgi Georgiev
AKAnja Klemmer
Anja Klemmer
CBChelsea Brain
Chelsea Brain
NMNicola J Mutch
Nicola J Mutch
Key Points: PolyP significantly augments the plasminogen activator capacity of FXIIa. Platelet-bound fibrin acts as a reservoir for plasminogen, FXII(a), and polyP.

1 March 2021 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
RGRenato Simões Gaspar
Renato Simões Gaspar
PFPlinio M. Ferreira
Plinio M. Ferreira
JMJoanne L. Mitchell
Joanne L. Mitchell
GPGiordano Pula
Giordano Pula
JGJonathan M. Gibbins
Jonathan M. Gibbins
Platelets release platelet-derived extracellular vesicles (PDEVs) upon activation - in a process that is regulated by generation of reactive oxygen species (ROS). Platelet NADPH oxidase-1 (Nox-1) contributes to ROS generation and thrombus formation downstream of the collagen receptor GPVI. We aimed to investigate whether PDEVs contain Nox-1 and whether this is relevant for PDEV-induced platelet activation. PDEVs were isolated through serial centrifugation after platelet activation with thrombin receptor agonist TRAP-6 (activated PDEVs) or in the absence of agonist (resting PDEVs). The physical properties of PDEVs were analyzed through nanoparticle tracking analysis. Nox-1 levels, fibrinogen binding and P-selectin exposure were measured using flow cytometry, and protein levels quantified by immunoblot analysis. ROS were quantified using DCF fluorescence and electron paramagnetic resonance. Nox-1 was found to be increased on the platelet outer membrane upon activation and was present in PDEVs. PDEVs induced platelet activation, while co-addition of GPVI agonist collagen-related peptide (CRP) did not potentiate this response. PDEVs were shown to be able to generate superoxide in a process at least partially mediated by Nox-1, while Nox-1 inhibition with ML171 (also known as 2-APT) did not influence PDEV production. Finally, inhibition of Nox-1 abrogated PDEV-mediated platelet activation. PDEVs are able to generate superoxide, bind to and activate platelets in a process mediated by Nox-1. These data provide novel mechanisms by which Nox-1 potentiates platelet responses, thus proposing Nox-1 inhibition as a feasible strategy to treat and prevent thrombotic diseases.

19 October 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
JDJoanne L. Dunster
Joanne L. Dunster
ABAlexander P. Bye
Alexander P. Bye
NKNeline Kriek
Neline Kriek
TSTanya Sage
Tanya Sage
JMJoanne Louise Mitchell
Joanne Louise Mitchell
JGJonathan M. Gibbins
Jonathan M. Gibbins
Accurate and comprehensive assessment of platelet function across cohorts of donors may be key to understanding the risk of thrombotic events associated with cardiovascular disease, and, hence, to help personalize the application of antiplatelet drugs. However, platelet function tests can be difficult to perform and analyze; they also can be unreliable or uninformative and poorly standardized across studies. The Platelet Phenomic Analysis (PPAnalysis) assay and associated open-source software platform were developed in response to these challenges. PPAnalysis utilizes preprepared freeze-dried microtiter plates to provide a detailed characterization of platelet function. The automated analysis of the high-dimensional data enables the identification of subpopulations of donors with distinct platelet function phenotypes. Using this approach, we identified that the sensitivity of a donor’s platelets to an agonist and their capacity to generate a functional response are distinct independent metrics of platelet reactivity. Hierarchical clustering of these metrics identified 6 subgroups with distinct platelet phenotypes within healthy cohorts, indicating that platelet reactivity does not fit into the traditional simple categories of “high” and “low” responders. These platelet phenotypes were found to exist in 2 independent cohorts of healthy donors and were stable on recall. PPAnalysis is a powerful tool for stratification of cohorts on the basis of platelet reactivity that will enable investigation of the causes and consequences of differences in platelet function and drive progress toward precision medicine.

1 January 1994 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
SHS. L. Hill
S. L. Hill
DBD. Bilton
D. Bilton
MJM. M. Johnson
M. M. Johnson
APAnita Pye
Anita Pye
JMJ. L. Mitchell
J. L. Mitchell
RSR. A. Stockley
R. A. Stockley
Sputum and serum pharmacokinetics of loracarbef (LY 163892) were performed in 19 patients with purulent bronchiectasis. Nine of the patients received 200 mg twice daily and ten patients, 400 mg twice daily, for a total of 14 days. β-Lactamase activity was measurable in the lung secretions of all 19 patients at the start of therapy. Mean peak serum concentrations of 11.7 mg/L (S.E.M. 1.7) were recorded at 1 h after administration of 200 mg doses on day 2 of therapy and were 18.5 mg/L (S.E.M. 1.9) at 1.5 h in the 400 mg group. Loracarbef was shown to penetrate lung secretions even in the presence of β-lactamase activity. Mean peak sputum concentrations were achieved between 2 and 4 h following dosing and were 0.2 mg/L (S.E.M. 0.05) in the 200 mg group and 0.4 mg/L (S.E.M. 0.08) in the 400 mg group. On days 7 and 14 of therapy, sputum loracarbef concentrations were similar 4 h after the morning dose (0.23 mg/L following 200 mg; 0.35 mg/L after 400 mg). These concentrations were approximately 2% of the peak serum concentration and penetration into lung secretions is similar to other beta-lactams.